Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Letters

• Publication date

  1996-10-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0304-3835(96)04372-8PMID 8947520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck.

  1995cited by this paper
• Genomic instability and loh at 2 polymorphic sites in the h-ras1 gene.

  1994cited by this paper
• A method to detect and quantitate the expression of normal versus mutant h-ras transcripts at codon-12.

  1994cited by this paper
• Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder.

  1994cited by this paper
• Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.

  1994cited by this paper
• Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study.

  1994cited by this paper
• p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns

  1994cited by this paper
• Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

  1993cited by this paper
• An association between the risk of cancer and mutations in the HRAS1 minisatellite locus.

  1993cited by this paper
• Screening of human bladder tumors and urine sediments for the presence of H‐ras mutations

  1993cited by this paper
• Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing.

  1993cited by this paper
• Microsatellite instability in bladder cancer.

  1993cited by this paper
• High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.

  1993cited by this paper
• H-ras oncogene mutations in the urine of patients with bladder-tumors - description of a noninvasive method for the detection of neoplasia.

  1992cited by this paper
• Frequent association of p53 gene mutation in invasive bladder cancer.

  1992cited by this paper
• Expression of ras Rb1 and p53 proteins in human breast cancer.

  1992cited by this paper
• Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.

  1991cited by this paper
• Identification of p53 gene mutations in bladder cancers and urine samples.

  1991cited by this paper
• Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.

  1990cited by this paper
• The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review).

  1990cited by this paper
• Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma.

  1990cited by this paper
• Biology and management of bladder cancer.

  1990cited by this paper
• Oncogenes and onco‐suppressor genes: Their involvement in cancer

  1989cited by this paper
• In vitro cell transformation by ras oncogenes.

  1989cited by this paper
• Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• ras genes.

  1987cited by this paper
• Differential expression of the ras gene family in mice

  1987cited by this paper
• Loss of genes on the short arm of chromosome 11 in bladder cancer

  1985cited by this paper
• Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours.

  1985cited by this paper
• Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors.

  1985cited by this paper
• ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma

  1985cited by this paper
• Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum.

  1984cited by this paper
• Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue

  1983cited by this paper

• Conformational fluidity of intrinsically disordered proteins in crowded environment: a molecular dynamics simulation study

  2024cites this paper
• MyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis

  2024cites this paper
• G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting

  2023cites this paper
• Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder

  2021cites this paper
• Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members

  2021cites this paper
• Design, Synthesis, and Evaluation of Novel p-(Methylthio)styryl Substituted Quindoline Derivatives as Neuroblastoma RAS (NRAS) Repressors via Specific Stabilizing the RNA G-Quadruplex.

  2018cites this paper
• Pseudogenes in gastric cancer pathogenesis: a review article

  2017cites this paper
• Incorporating VEGF-targeted therapy in advanced urothelial cancer

  2017cites this paper
• K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth

  2016cites this paper
• Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.

  2015cites this paper
• Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.

  2015cites this paper
• The role of WNT signalling in urothelial cell carcinoma.

  2015cites this paper
• HRAS is silenced by two neighboring G-quadruplexes and activated by MAZ, a zinc-finger transcription factor with DNA unfolding property

  2014cites this paper
• Investigation of the pharmacological profiles of dinuclear metal complexes as novel, potent and selective cytotoxic agents against ras-transformed cells.

  2014cites this paper
• Role of Cyclooxygenase-2 Enzyme in Human Transitional Cell Carcinoma of the Urinary Bladder

  2013cites this paper
• CYCLOOXYGENASE -2 AND CANCER: A silent link with fatal ending.

  2013cites this paper
• The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed

  2013cites this paper
• Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium.

  2013cites this paper
• Guanidino anthrathiophenediones as G-quadruplex binders: uptake, intracellular localization, and anti-Harvey-Ras gene activity in bladder cancer cells.

  2013cites this paper
• Activation of RAS Genes by Specific Point Mutations in Transitional Cell Carcinoma of Urinary Bladder in Kashmiri Population

  2012cites this paper
• Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9)

  2012cites this paper
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

  2011cites this paper
• Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis

  2011cites this paper
• G4-DNA Formation in the HRAS Promoter and Rational Design of Decoy Oligonucleotides for Cancer Therapy

  2011cites this paper
• The Role of Oncogene Activation in Tumor Progression

  2010cites this paper
• Inhibitory effect of flavonoids on mutant H-Rasp21 protein

  2010cites this paper
• Stimulatory effects of the multi‐kinase inhibitor sorafenib on human bladder cancer cells

  2010cites this paper
• Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer.

  2009cites this paper
• Bladder cancer: modeling and translation.

  2009cites this paper
• Activation of RAS family genes in urothelial carcinoma.

  2009cites this paper
• Mutations of RAS gene family in specimens of bladder cancer.

  2008cites this paper
• Gene expression profiling of chemically induced rat bladder tumors.

  2007cites this paper
• Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

  2007cites this paper
• The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

  2006cites this paper
• RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras.

  2006cites this paper
• Down-regulation of S100C is associated with bladder cancer progression and poor survival.

  2005cites this paper
• A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

  2005cites this paper
• Human RAS Superfamily Proteins and Related GTPases

  2004cites this paper
• H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells

  2004cites this paper
• p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis

  2004cites this paper
• Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

  2004cites this paper
• Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine.

  2004cites this paper
• Ras superfamily monomeric G proteins in carcinoma cell motility.

  2003cites this paper
• Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study.

  2003cites this paper
• The role of Ras superfamily proteins in bladder cancer progression.

  2003cites this paper
• Prospects for anti‐ras drugs

  2002cites this paper
• Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?

  2002cites this paper
• Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation

  2001cites this paper
• Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.

  2000cites this paper
• Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome

  2000cites this paper
• Cyclooxygenase-2 Expression Is Up-Regulated in Transitional Cell Carcinoma and Its Preneoplastic Lesions in the Human Urinary Bladder 1

  2000cites this paper
• Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.

  2000cites this paper
• Transcriptional activation of the ras oncogenes and implications of BRCA1 in the cell cycle regulation through p53 checkpoint

  1999cites this paper
• Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.

  1999cites this paper
• Differential expression and mutation of the ras family genes in human breast cancer.

  1998cites this paper
• Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression

  1998cites this paper
• Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes.

  1998cites this paper
• Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.

  1998cites this paper
• Expression of ras proto-oncogenes: regulation and implications in the development of human tumors.

  1997cites this paper